Patents by Inventor Elizabeth Stockert

Elizabeth Stockert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
    Patent number: 9283276
    Abstract: The present invention relates to antibodies, particularly antibody 175, and fragments thereof or antibodies derived therefrom, which bind to the EGF receptor, particularly to amplified or overexpressed epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. These antibodies are useful in the diagnosis and treatment of cancer. Recombinant or hybrid antibodies having the variable region heavy or light chain sequence(s) of antibody 175 are also provided. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: March 15, 2016
    Assignee: Ludwig Institute for Cancer Research Ltd.
    Inventors: Terrance Grant Johns, Elizabeth Stockert, Stephen Stockert, Lloyd J. Old, Andrew M. Scott, Veronika M. Rayzman
  • SPECIFIC BINDING PROTEINS AND USES THEREOF
    Publication number: 20110313230
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: April 1, 2011
    Publication date: December 22, 2011
    Inventors: Terrance Grant Johns, Andrew Mark Scott, Gerd Ritter, Achim Jungbluth, Elizabeth Stockert, Stephen Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark, Lloyd J. Old, Edward B. Reilly, Andrew C. Phillips, Jonathan A. Meulbroek, Fritz G. Buchanan
  • SPECIFIC BINDING PROTEINS AND USES THEREOF
    Publication number: 20110293511
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: April 1, 2011
    Publication date: December 1, 2011
    Inventors: Terrance Grant Johns, Andrew Mark Scott, Gerd Ritter, Achim Jungbluth, Elizabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark, Lloyd J. Old, Edward B. Reilly, Andrew C. Phillips, Jonathan A. Meulbroek, Fritz G. Buchanan, Stephen Stockert
  • MONOCLONAL ANTIBODY 175 TAGETING THE EGF RECEPTOR AND DERIVATIVES AND USES THEREOF
    Publication number: 20110150759
    Abstract: The present invention relates to antibodies, particularly antibody 175, and fragments thereof or antibodies derived therefrom, which bind to the EGF receptor, particularly to amplified or overexpressed epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. These antibodies are useful in the diagnosis and treatment of cancer. Recombinant or hybrid antibodies having the variable region heavy or light chain sequence(s) of antibody 175 are also provided. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: August 14, 2008
    Publication date: June 23, 2011
    Inventors: Terrance Grant Johns, Elizabeth Stockert, Stephan Stockert, Lioyd J. Old
  • SPECIFIC BINDING PROTEINS AND USES THEREOF
    Publication number: 20110076232
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: September 24, 2010
    Publication date: March 31, 2011
    Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew Mark Scott, Christoph Renner, Achim Jungbluth, Elizabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark, Gerd Ritter
  • Isolated cancer associated antigens NY-MEL 1 and NY-MEL 3, peptides based thereon, and their uses
    Patent number: 7132507
    Abstract: The invention relates to isolated, cancer associated antigens, nucleic acid molecules, and various uses thereof.
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: November 7, 2006
    Assignees: Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, Cornell Research Foundation, Inc.
    Inventors: Dirk Jager, Elizabeth Stockert, Matthew Scanlan, Ali Gure, Elke Jager, Alexander Knuth, Lloyd Old, Yao-Tseng Chen
  • Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
    Patent number: 6911529
    Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also part of this invention.
    Type: Grant
    Filed: June 22, 2000
    Date of Patent: June 28, 2005
    Assignees: Ludwig Institute for Cancer Research, Cornell Research Foundation, Memorial Sloan-Kettering Cancer Center
    Inventors: Dirk Jager, Elizabeth Stockert, Matthew Scanlan, Ali Gure, Elke Jager, Alexander Knuth, Lloyd Old, Yao-tseng Chen
  • Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
    Patent number: 6774226
    Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.
    Type: Grant
    Filed: November 30, 1999
    Date of Patent: August 10, 2004
    Assignees: Ludwig Institute for Cancer Research, Cornell Research Foundation, Inc.
    Inventors: Dirk Jager, Elizabeth Stockert, Matthew Scanlan, Ali Gure, Elke Jager, Alexander Knuth, Lloyd Old, Yao-tseng Chen
  • Isolated cancer associated antigens NY-MEL 1 and NY-MEL 3, peptides based thereon, and their uses
    Publication number: 20030017547
    Abstract: The invention relates to isolated, cancer associated antigens, nucleic acid molecules, and various uses thereof.
    Type: Application
    Filed: May 21, 2002
    Publication date: January 23, 2003
    Inventors: Dirk Jager, Elizabeth Stockert, Matthew Scanlan, Ali Gure, Elke Jager, Alexander Knuth, Lloyd Old, Yao-Tseng Chen
  • Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
    Patent number: 6448073
    Abstract: The invention relates to isolated, cancer associated antigens, nucleic acid molecules, and various uses thereof.
    Type: Grant
    Filed: January 28, 2000
    Date of Patent: September 10, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Dirk Jager, Elizabeth Stockert, Matthew Scanlan, Ali Gure, Elke Jager, Alexander Knuth, Lloyd Old, Yao-tseng Chen